liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Editorial: Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics: in Acta Dermato-Venereologica(ISSN 0001-5555), vol 87, issue 6, pp 485-492
Research and Development, ACO HUD Nordic AB, Upplands Väsby, Sweden, ACO Hud Nordic AB, Box 622, SE-194 26 Upplands Väsby, Sweden.
Stockholm Consumer Cooperative Society, Stockholm, Sweden.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Dermatology and Venerology . Östergötlands Läns Landsting, Centre for Medicine, Department of Dermatology and Venerology in Östergötland.
2007 (English)Other (Other (popular science, discussion, etc.))
Abstract [en]

Marketing of cosmetics often makes strong claims linked to active ingredients. This is especially so for anti-ageing products, where the presentation and content of "active" ingredients may create new difficulties in their classification as cosmetics or medicinal products. A recent change in European legislation classifies a product as medicinal by virtue of its "function", in addition to the previous definition of "presentation" (i.e. marketing linked to diseases). Thus, formulations that also restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action should henceforth be covered by the Medicinal Products Directive. A cosmetic product must be suitable for its purpose and should not lead to adverse reactions that are disproportional in relation to its intended effect. However, the forthcoming ban on animal testing of cosmetic ingredients and the new European regulation, REACH (Registration, Evaluation and Authorisation of Chemicals), which aims to ensure a high level of chemical safety to protect human health and the environment, will probably have limited impact on the safety assessment of cosmetics. In order to enable consumers to make informed purchasing decisions, greater transparency in the process of assessing the performance of cosmetics is needed. Introduction of a more transparent system, enabling consumers and professionals to examine the scientific evidence for the claimed effect and the safety assessment of cosmetics, is therefore timely. Lack of transparency increases the risk of consumers wasting money on cosmetics that do not deliver the desired effects. This may jeopardize public trust in the cosmetic industry.

Place, publisher, year, edition, pages
2007. Vol. 87, no 6, 485-492 p.
Keyword [en]
Claim substantiation, Efficacy, Misleading, Pharmaceuticals, Safety
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-47544DOI: 10.2340/00015555-0311OAI: diva2:268440
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2010-05-24

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Serup, Jörgen
By organisation
Faculty of Health SciencesDermatology and Venerology Department of Dermatology and Venerology in Östergötland
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 116 hits
ReferencesLink to record
Permanent link

Direct link